LYVE-1 Antibody (E9VA4): sc-65647

LYVE-1 Antibody (E9VA4) is a rat monoclonal IgM antibody that detects the LYVE-1 protein of mouse origin by western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). Anti-LYVE-1 antibody (E9VA4) is available as the non-conjugated format. Lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) plays a crucial role in the lymphatic system by mediating the interaction between lymphatic endothelial cells and hyaluronan, a glycosaminoglycan that is abundant in the extracellular matrix. This interaction is vital for maintaining lymphatic vessel integrity and facilitating lymphatic transport, which is essential for immune responses and tissue homeostasis. LYVE-1 is predominantly expressed on the surface of lymphatic endothelial cells and is significantly involved in lymphangiogenesis, the formation of new lymphatic vessels from pre-existing ones, which is particularly important in the context of tumor progression and metastasis. LYVE-1 expression is largely restricted to endothelial cells lining lymphatic vessels and splenic sinusoidal endothelial cells, making LYVE-1 a specific marker for lymphatic vessels. LYVE-1 binds to both soluble and immobilized hyaluronan with greater specificity than other receptors, such as HCAM, and is completely absent from blood vessels, underscoring LYVE-1′s unique role in lymphatic biology. LYVE-1 research is critical for understanding the mechanisms of lymphatic-related diseases and for developing therapeutic strategies targeting lymphangiogenesis in cancer and other conditions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

LYVE-1 Antibody (E9VA4) References:

1. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan.  |  Banerji, S., et al. 1999. J Cell Biol. 144: 789-801. PMID: 10037799
2. Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis.  |  Jackson, DG. 2004. APMIS. 112: 526-38. PMID: 15563314
3. Normal lymphatic development and function in mice deficient for the lymphatic hyaluronan receptor LYVE-1.  |  Gale, NW., et al. 2007. Mol Cell Biol. 27: 595-604. PMID: 17101772
4. Lack of lymphatic vessel phenotype in LYVE-1/CD44 double knockout mice.  |  Luong, MX., et al. 2009. J Cell Physiol. 219: 430-7. PMID: 19170073
5. Clinical implications of increased lymph vessel density in the lymphatic metastasis of early-stage invasive cervical carcinoma: a clinical immunohistochemical method study.  |  Zhang, SQ., et al. 2009. BMC Cancer. 9: 64. PMID: 19232130
6. LYVE-1 immunocytochemical staining for gastrointestinal carcinoids.  |  Tomita, T. 2009. Pathology. 41: 248-53. PMID: 19291537
7. Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma.  |  Guo, B., et al. 2009. Anat Rec (Hoboken). 292: 633-9. PMID: 19382240
8. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis.  |  Kubota, Y., et al. 2009. J Exp Med. 206: 1089-102. PMID: 19398755
9. Lymphatic vessel density in correlation to lymph node metastasis in head and neck squamous cell carcinoma.  |  Frech, S., et al. 2009. Anticancer Res. 29: 1675-9. PMID: 19443385
10. Expression of lymphatic endothelium-specific hyaluronan receptor LYVE-1 in the developing mouse kidney.  |  Lee, HW., et al. 2011. Cell Tissue Res. 343: 429-44. PMID: 21181199
11. Hyaluronan Receptor LYVE-1-Expressing Macrophages Maintain Arterial Tone through Hyaluronan-Mediated Regulation of Smooth Muscle Cell Collagen.  |  Lim, HY., et al. 2018. Immunity. 49: 326-341.e7. PMID: 30054204
12. LYVE-1+ macrophages form a collaborative CCR5-dependent perivascular niche that influences chemotherapy responses in murine breast cancer.  |  Anstee, JE., et al. 2023. Dev Cell. 58: 1548-1561.e10. PMID: 37442140

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-LYVE-1 Antibody (E9VA4) has 8 citations in a variety of scientific publications.

Primary antibodies like Anti-LYVE-1 Antibody (E9VA4) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

LYVE-1 Antibody (E9VA4) Specifications

Alternate Product Name: LYVE1

Product Clone Name: E9VA4

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgM

Amino Acids:

Epitope Target: LYVE-1

Epitope Species: mouse

Product Reactivity/Detection: LYVE-1

Species Reactivity/Detection: mouse

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF

Vialing Information: Each vial contains 200 µg IgM in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 8 citations in various scientific publications

Available Conjugates/Forms for LYVE-1 Antibody (E9VA4): N/A